Cargando…
Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line
Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell prolifera...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103245/ https://www.ncbi.nlm.nih.gov/pubmed/33804833 http://dx.doi.org/10.3390/cells10040716 |
_version_ | 1783689279966281728 |
---|---|
author | Saafan, Hisham Alahdab, Ahmad Michelet, Robin Gohlke, Linus Ziemann, Janine Holdenrieder, Stefan McLaughlin, Katie-May Wass, Mark N. Cinatl, Jindrich Michaelis, Martin Kloft, Charlotte Ritter, Christoph A |
author_facet | Saafan, Hisham Alahdab, Ahmad Michelet, Robin Gohlke, Linus Ziemann, Janine Holdenrieder, Stefan McLaughlin, Katie-May Wass, Mark N. Cinatl, Jindrich Michaelis, Martin Kloft, Charlotte Ritter, Christoph A |
author_sort | Saafan, Hisham |
collection | PubMed |
description | Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell proliferation regulating inhibitor of protein phosphatase 2A (CIP2A) in the HCC4006rErlo0.5 NSCLC cell line adapted to erlotinib as a model of acquired drug resistance. Constitutive CIP2A resulted in a constitutive activation of Akt signaling. The proteasome inhibitor bortezomib was able to reduce CIP2A levels, which resulted in an activation of protein phosphatase 2A and deactivation of Akt. Combination experiments with erlotinib and bortezomib revealed a lack of interaction between the two drugs. However, the effect size of bortezomib was higher in HCC4006rErlo0.5, compared to the erlotinib-sensitive HCC4006 cells, as indicated by an increase in Emax (0.911 (95%CI 0.867–0.954) vs. 0.585 (95%CI 0.568–0.622), respectively) and decrease in EC50 (52.4 µM (95%CI 46.1–58.8 µM) vs. 73.0 µM (95%CI 60.4–111 µM), respectively) in the concentration–effect model, an earlier onset of cell death induction, and a reduced colony surviving fraction (0.38 ± 0.18 vs. 0.95 ± 0.25, respectively, n = 3, p < 0.05). Therefore, modulation of CIP2A with bortezomib could be an interesting approach to overcome drug resistance to erlotinib treatment in NSCLC. |
format | Online Article Text |
id | pubmed-8103245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81032452021-05-08 Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line Saafan, Hisham Alahdab, Ahmad Michelet, Robin Gohlke, Linus Ziemann, Janine Holdenrieder, Stefan McLaughlin, Katie-May Wass, Mark N. Cinatl, Jindrich Michaelis, Martin Kloft, Charlotte Ritter, Christoph A Cells Article Exploring mechanisms of drug resistance to targeted small molecule drugs is critical for an extended clinical benefit in the treatment of non-small cell lung cancer (NSCLC) patients carrying activating epidermal growth factor receptor (EGFR) mutations. Here, we identified constitutive cell proliferation regulating inhibitor of protein phosphatase 2A (CIP2A) in the HCC4006rErlo0.5 NSCLC cell line adapted to erlotinib as a model of acquired drug resistance. Constitutive CIP2A resulted in a constitutive activation of Akt signaling. The proteasome inhibitor bortezomib was able to reduce CIP2A levels, which resulted in an activation of protein phosphatase 2A and deactivation of Akt. Combination experiments with erlotinib and bortezomib revealed a lack of interaction between the two drugs. However, the effect size of bortezomib was higher in HCC4006rErlo0.5, compared to the erlotinib-sensitive HCC4006 cells, as indicated by an increase in Emax (0.911 (95%CI 0.867–0.954) vs. 0.585 (95%CI 0.568–0.622), respectively) and decrease in EC50 (52.4 µM (95%CI 46.1–58.8 µM) vs. 73.0 µM (95%CI 60.4–111 µM), respectively) in the concentration–effect model, an earlier onset of cell death induction, and a reduced colony surviving fraction (0.38 ± 0.18 vs. 0.95 ± 0.25, respectively, n = 3, p < 0.05). Therefore, modulation of CIP2A with bortezomib could be an interesting approach to overcome drug resistance to erlotinib treatment in NSCLC. MDPI 2021-03-24 /pmc/articles/PMC8103245/ /pubmed/33804833 http://dx.doi.org/10.3390/cells10040716 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Saafan, Hisham Alahdab, Ahmad Michelet, Robin Gohlke, Linus Ziemann, Janine Holdenrieder, Stefan McLaughlin, Katie-May Wass, Mark N. Cinatl, Jindrich Michaelis, Martin Kloft, Charlotte Ritter, Christoph A Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line |
title | Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line |
title_full | Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line |
title_fullStr | Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line |
title_full_unstemmed | Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line |
title_short | Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line |
title_sort | constitutive cell proliferation regulating inhibitor of protein phosphatase 2a (cip2a) mediates drug resistance to erlotinib in an egfr activating mutated nsclc cell line |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103245/ https://www.ncbi.nlm.nih.gov/pubmed/33804833 http://dx.doi.org/10.3390/cells10040716 |
work_keys_str_mv | AT saafanhisham constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT alahdabahmad constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT micheletrobin constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT gohlkelinus constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT ziemannjanine constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT holdenriederstefan constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT mclaughlinkatiemay constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT wassmarkn constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT cinatljindrich constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT michaelismartin constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT kloftcharlotte constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline AT ritterchristopha constitutivecellproliferationregulatinginhibitorofproteinphosphatase2acip2amediatesdrugresistancetoerlotinibinanegfractivatingmutatednsclccellline |